- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Abeona Therapeutics Inc (ABEO)
Abeona Therapeutics Inc stock price live, this page displays NASDAQ ABEO stock exchange data. View the ABEO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Abeona Therapeutics Inc real time stock price chart below.
What Is the Abeona Therapeutics Inc Stock Price Today?
The Abeona Therapeutics Inc stock price today is 6.0900.
What Is the Stock Symbol for Abeona Therapeutics Inc?
The stock symbol for Abeona Therapeutics Inc is "ABEO."
What Stock Exchange Does Abeona Therapeutics Inc Trade On?
Abeona Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Abeona Therapeutics Inc a Good Stock to Buy?
Determining whether Abeona Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABEO quote. (ISIN: US00289Y2063)
What Is the Abeona Therapeutics Inc Stock Price Today?
The Abeona Therapeutics Inc stock price today is 6.0900.
What Is the Stock Symbol for Abeona Therapeutics Inc?
The stock symbol for Abeona Therapeutics Inc is "ABEO."
What Stock Exchange Does Abeona Therapeutics Inc Trade On?
Abeona Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Abeona Therapeutics Inc a Good Stock to Buy?
Determining whether Abeona Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABEO quote. (ISIN: US00289Y2063)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.0100
6.1400
52 wk Range
4.0000
7.6500
ABEO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.01006.1400
52 wk Range
4.00007.6500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABEO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
18.8571
Upside
+209.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 18.8571
(+209.64% Upside)
Abeona Therapeutics Inc Earnings Call Summary for Q2/2026
- ZEVASKYN Q2 revenue reached $11.4M, up 31% sequentially but missed $12.24M estimate; shares dropped 10.99% to $6.64 in premarket trading.
- Net loss widened to $20.2M ($0.35/share) from Q1's $17.1M as company scaled commercial operations and treatment center network to 7 sites.
- Manufacturing issues prevented revenue recognition for 2 of 5 treated patients; gross margin at 63% vs. long-term target of 85-90% at full capacity.
- CMS granted ZEVASKYN New Technology Add-on Payment status for fiscal 2027, expected to improve hospital reimbursement for Medicare patients.
- Company ended quarter with $146.8M cash; no formal guidance issued but management targets steady treatment cadence with 40% patient population access.
Last Updated: 2026/08/13, 15:42
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
-0,35 / -0,22
Revenue / Forecast
11,38M / 12,24M
Compare ABEO to Peers and Sector
Metrics to compare | ABEO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABEOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.5x | 5.8x | −0.4x | |
PEG Ratio | 0.03 | −0.21 | 0.00 | |
Price/Book | 2.7x | 2.6x | 2.6x | |
Price / LTM Sales | 13.6x | 7.6x | 3.1x | |
Upside (Analyst Target) | 179.1% | 143.9% | 48.9% | |
Fair Value Upside | Unlock | 15.5% | 6.2% | Unlock |
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Abeona Therapeutics (ABEO) Stock Price Today?
The Abeona Therapeutics stock price today is 6,0900 USD.
What Stock Exchange Does Abeona Therapeutics Trade On?
Abeona Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Abeona Therapeutics?
The stock symbol for Abeona Therapeutics is "ABEO."
What Is the Abeona Therapeutics Market Cap?
As of today, Abeona Therapeutics market cap is 348,2500M USD.
What Is Abeona Therapeutics's Earnings Per Share (TTM)?
The Abeona Therapeutics EPS (TTM) is -1,1840.
When Is the Next Abeona Therapeutics Earnings Date?
Abeona Therapeutics will release its next earnings report on Nov 16, 2026.
From a Technical Analysis Perspective, Is ABEO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Abeona Therapeutics Stock Split?
Abeona Therapeutics has split 4 times.
How Many Employees Does Abeona Therapeutics Have?
Abeona Therapeutics has 226 employees.
What is the current trading status of Abeona Therapeutics (ABEO)?
As of Aug 23, 2026, Abeona Therapeutics (ABEO) is trading at a price of 6,0900 USD, with a previous close of 5,9600 USD. The stock has fluctuated within a day range of 6,0100 USD to 6,1400 USD, while its 52-week range spans from 4,0000 USD to 7,6500 USD.
What Is Abeona Therapeutics (ABEO) Price Target According to Analysts?
The average 12-month price target for Abeona Therapeutics is 18,8571 USD, with a high estimate of 28 USD and a low estimate of 14 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +209,64% Upside potential.
What Is the ABEO Premarket Price?
ABEO's last pre-market stock price is 6,0428 USD. The pre-market share volume is 830,0000, and the stock has decreased by 0,0828, or 1,3900%.
What Is the ABEO After Hours Price?
ABEO's last after hours stock price is 6,1019 USD, the stock has decreased by 0,0119, or 0,2000%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.